Protagonist Therapeutics
$99.21
23
-$0.31-0.31% Tuesday 20:00
Statistics
Day High
101.21
Day Low
97.45
52W High
105.98
52W Low
42.01
Volume
382,490
Avg. Volume
-
Mkt Cap
6.33B
P/E Ratio
-
Dividend Yield
-
Dividend
-
Earnings
5MayExpected
Expected EPS
-0.65
Actual EPS
0.05
Financials
-282.83%Profit Margin
Unprofitable92.03MRevenue
-260.3MNet Income
Analyst Ratings
112.64Average Price Target
The highest estimate is 125.00.
From 11 ratings within the last 6 months. This is not an investment recommendation.
From 11 ratings within the last 6 months. This is not an investment recommendation.
Buy 82%
Hold 18%
Sell 0%
People Also Follow
This list is based on the watchlists of people on Stock Events who follow PTGX. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
Arvinas
ARVN
Mkt Cap695.5M
CRISPR Therapeutics
CRSP
Mkt Cap4.98B
Novartis
NVS
Mkt Cap279.67B
AMGEN
AMGN
Mkt Cap178B
Gilead Sciences
GILD
Mkt Cap163.4B
Regeneron Pharmaceuticals
REGN
Mkt Cap73.54B
Vertex Pharmaceuticals
VRTX
Mkt Cap107.83B
About
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PN-943, an oral, alpha-4-beta-7 integrin- specific antagonist peptide that is in Phase II clinical trials for treating inflammatory bowel disease (IBD); and PN-235, an orally delivered interleukin-23 receptor specific antagonist for the treatment of IBD and non-IBD indications. The company has a license and collaboration agreement with Janssen Biotech, Inc. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
Show more...
CEO
Dr. Dinesh V. Patel Ph.D.
Employees
124
Country
United States
ISIN
US74366E1029
Listings
0 Comments
Share your thoughts
FAQ
What is Protagonist Therapeutics stock price today?▼
The current price of PTGX is $99.21 USD — it has decreased by -0.31% in the past 24 hours. Watch Protagonist Therapeutics stock price performance more closely on the chart.
What is Protagonist Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Protagonist Therapeutics stocks are traded under the ticker PTGX.
Is Protagonist Therapeutics stock price growing?▼
PTGX stock has risen by +0.7% compared to the previous week, the month change is a -3.58% fall, over the last year Protagonist Therapeutics has showed a +136.16% increase.
What is Protagonist Therapeutics market cap?▼
Today Protagonist Therapeutics has the market capitalization of 6.33B
What were Protagonist Therapeutics earnings last quarter?▼
PTGX earnings for the last quarter are 0.05 USD per share, whereas the estimation was -0.65 USD resulting in a +107.69% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Protagonist Therapeutics revenue for the last year?▼
Protagonist Therapeutics revenue for the last year amounts to 92.03M USD.
What is Protagonist Therapeutics net income for the last year?▼
PTGX net income for the last year is -260.3M USD.
How many employees does Protagonist Therapeutics have?▼
As of May 06, 2026, the company has 124 employees.
In which sector is Protagonist Therapeutics located?▼
Protagonist Therapeutics operates in the Health & Wellness sector.
When did Protagonist Therapeutics complete a stock split?▼
Protagonist Therapeutics has not had any recent stock splits.
Where is Protagonist Therapeutics headquartered?▼
Protagonist Therapeutics is headquartered in Newark, United States.